Biotinylated Recombinant Epstein-Barr Virus Epstein-Barr Nuclear Antigen 1 (EBNA1) Protein (MBP&His-Avi)

Name: Biotinylated Recombinant Epstein-Barr Virus Epstein-Barr Nuclear Antigen 1 (EBNA1) Protein (MBP&His-Avi)
Brand: Beta LifeScience
SKU: BLC-00473P
Price: 815.2 USD
Availability: InStock

Greater than 85% as determined by SDS-PAGE.

Collections: Avi-tagged proteins, Biotinylated proteins, Featured biotinylated protein molecules, Featured viral antigens molecules, Other viral antigens, Recombinant proteins, Viral antigen

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Biotinylated Recombinant Epstein-Barr Virus Epstein-Barr Nuclear Antigen 1 (EBNA1) Protein (MBP&His-Avi) is produced by our E.coli expression system. This is a protein fragment.
Purity	Greater than 85% as determined by SDS-PAGE.
Uniprotkb	P03211
Target Symbol	EBNA1
Species	Epstein-Barr virus (strain B95-8) (HHV-4) (Human herpesvirus 4)
Expression System	E.coli
Tag	N-MBP&C-6His-Avi
Target Protein Sequence	RRKKGGWFGKHRGQGGSNPKFENIAEGLRALLARSHVERTTDEGTWVAGVFVYGGSKTSLYNLRRGTALAIPQCRLTPLSRLPFGMAPGPGPQPGPLRESIVCYFMVFLQTHIFAEVLKDAIKDLVMTKPAPTCNIRVTVCSFDDGVDLPPWFPPMVEGAAAEGDDGDDGDEGGDGDEGEEGQE
Expression Range	458-641aa
Protein Length	Partial
Mol. Weight	67.6 kDa
Research Area	Microbiology
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Plays an essential role in replication and partitioning of viral genomic DNA during latent viral infection. During this phase, the circular double-stranded viral DNA undergoes replication once per cell cycle and is efficiently partitioned to the daughter cells. EBNA1 activates the initiation of viral DNA replication through binding to specific sites in the viral latent origin of replication, oriP. Additionally, it governs the segregation of viral episomes by mediating their attachment to host cell metaphase chromosomes. Also activates the transcription of several viral latency genes. Finally, it can counteract the stabilization of host p53/TP53 by host USP7, thereby decreasing apoptosis and increasing host cell survival.
Subcellular Location	Host nucleus.
Protein Families	Herpesviridae EBNA1 family
Database References	KEGG: vg:3783774

Gene Functions References

Endemic variants of EBNA1 play a significant role in EBV-driven carcinogenesis by altering key regulatory interactions that destabilize latent infection. PMID: 28077791
Epstein-Barr Virus EBNA1 bound to host genes of high significance for B-cell growth and function, including MEF2B, IL6R, and EBF1. PMID: 26468528
both LANA1 and EBNA1 undergo highly efficient +1/-2 programmed ribosomal frameshifting to generate previously undescribed alternative reading frame (ARF) proteins in their repeat regions. PMID: 25271323
Epstein-Barr virus EBNA1 protein regulates viral latency through effects on let-7 microRNA and dicer. PMID: 25031339
EBNA-1 miRNA targets human casp3 expression to inhibit apoptosis. PMID: 23503461
These results support the idea that the chromosome binding of EBNA1 is mediated by electrostatic interactions between the basic amino acids within the chromosome binding domains and negatively charged cellular chromatin. PMID: 23836915
There is no association between EBNA1 titers and multiple sclerosis in Indian populations. PMID: 23312038
EBNA1 is not naturally released from Epstein-Barr virus-infected cells as a source of antigen for CD4(+) T cell priming. PMID: 23569328
EBNA1 repeat mRNA sequence, not the encoded protein sequence, underlies immune evasion in this class of virus suggests a novel approach to therapeutic development through the use of anti-sense strategies or small molecules targeting EBNA1 mRNA structure. PMID: 23300450
EBNA1 binds specifically to many sites in the human genome and may regulate some cellular genes in infected cells. [review] PMID: 23325328
These findings highlight a previously unrecognized property of the interaction of EBNA1 with cellular chromatin that may fine-tune its function in the maintenance of viral latency. PMID: 23348225
EBNA1 may reset cellular transcription during infection and prime the infected cells for malignant transformation. PMID: 23358825
Data show that purified Epstein-Barr nuclear antigen 1 EBNA1 recruits purified Human Orc1 and Cdc6 onto replication origin oriP. PMID: 22589552
These results provide the first function for EBNA1 in lytic infection and show that EBNA1 interactions with PML IV lead to a loss of PML nuclear bodies (NBs) that promotes lytic infection. PMID: 22491455
Studies indicate that that EBNA1 is a very important protein for the development and/or progression of nasopharyngeal carcinoma. PMID: 22206863
Although the depletion of HMGB2 partly altered EBNA-1 association with chromatin in HeLa cells during interphase and mitosis, it did not significantly impact the maintenance of EBV episomes in Raji cells. PMID: 22345443
These findings support the hypothesis that Epstein-Barr virus EBNA1 initiates transcription at the C promoter via interactions between multiple EBNA1 homodimers and cellular transcription such as E2F1, ARID3A and Oct-2. PMID: 22302879
Report Epstein-Barr virus nuclear antigen-1 B-cell epitopes in multiple sclerosis twins. PMID: 21757535
PML disruption by EBNA1 is one mechanism by which EBV contribute to the development of gastric cancer. PMID: 22013060
EBNA1 of Epstein-Barr virus modulated cellular oxidative stress responses and promoted metastasis. PMID: 22013061
The pathogenesis of multiple sclerosis may involve intrathecal Epstein-Barr virus nuclear antigen-1 (EBNA-1) specific T cells susceptible to modulation by vitamin D. PMID: 22018702
These results provide evidence that EBNA1 is a new target for the transcription factor HSF1. PMID: 22018489
expression of EBNA1 induced telomere abnormalities including loss or gain of telomere signals, telomere fusion and heterogeneous length of telomeres PMID: 21394098
antibodies to the EBNA-1 protein cross-react with dsDNA PMID: 21245919
These data indicate that roscovitine effects are serine 393 specific and that serine 393 is important in EBNA1- and oriPCp-dependent transcription and episome persistence. PMID: 21209116
Epstein Barr virus-encoded EBNA1 interference with MHC class I antigen presentation reveals a close correlation between mRNA translation initiation and antigen presentation. PMID: 20976201
These results suggest that EBV encoded EBNA1 can contribute to the oncogenic process by up-regulating the apoptosis suppressor protein, survivin in EBV-associated B-lymphoma cells. PMID: 21093004
Findings reveal that RNA polymerase III-dependent EBER expression through induction of cellular transcription factors and add to the repertoire of EBNA1's transcription-regulatory properties. PMID: 20843307
EBNA1 can interact with a large number of cellular genes and chromosomal loci in latently infected cells, but that these sites are likely to represent a complex ensemble of direct and indirect EBNA1 binding sites. PMID: 20929547
an interaction between EBNA1 and the host CK2 kinase is crucial for EBNA1 to disrupt PML bodies and degrade PML proteins. PMID: 20719947
EBNA-1 may directly influence the transcription of a subset of genes PMID: 20706582
40 novel regions are identified in the human genome, constituted of tandemly repeated binding sites for EBNA1. PMID: 20655080
EBV infection with EBNA1 expression in gastric carcinomas provides advantages for host cell survival, growth ability and transformation potential involving escape from immunosurveillance PMID: 19956844
effect of EBNA1 on cellular gene expression by microarray analysis using the B cell BJAB and the epithelial 293 cell lines transfected with EBNA1 PMID: 20080792
findings suggest amino-terminal 379Lys-Arg380 is essential for EBNA-1 NLS & Ser385 phosphorylation up-regulates nuclear transport efficiency of EBNA-1 by increasing its binding affinity to NPI-1, while phosphorylation of Ser386 & Ser383 down-regulates it PMID: 16439554
The partitioning of EBNA1 molecules onto sister chromatids during cellular DNA replication underlies the non-stochastic segregation of extrachromosomally replicating viral genomes. PMID: 17405814
EBNA1 apparently disables TGF-beta signaling, which subsequently decreases transcription of the PTPRK tumor suppressor PMID: 17720884
The mechanism by which EBNA-1 represses Qp promoter through binding downstream of the transcription start site and the role of this autoregulatory function in EBV latency were addressed. PMID: 18077719
targeting EBNA1 to human DEC-205 receptor, in the presence of the DC maturation stimulus poly(I:C), expanded EBNA1-specific CD4 and CD8 memory T cells; these lymphocytes control the outgrowth of autologous EBV-infected B cells PMID: 18519810
low-level expression of p27 protein may partially attribute to latent EBV infection in extranodal nasal-type NK cell lymphoma involving EBNA1 PMID: 18769118
EBNA1-NT may act as a repressor of the HER2/neu oncogene PMID: 18805633
Epstein-Barr virus nuclear antigen-1 promotes genomic instability via induction of reactive oxygen species PMID: 19139406
EBNA1 regulates oriP replication by impeding the migration of replication forks, and upon binding the family of repeats it blocks the migration of transcription forks. PMID: 19265546
Phosphorylation-deficient mutant reduced its ability to activate transcription. PMID: 19439552
These findings suggest that the EBNA1 replication and maintenance function uses a common G-quadruplex binding capacity of LR1 and LR2. PMID: 19656898
USP7 can stimulate EBNA1-DNA interactions and EBNA1 can alter histone modification at oriP through recruitment of USP7. PMID: 19834552

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.